Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma
Biomolecules · 2025
DOI: 10.3390/biom15010076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Nadia St Thomas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Immunology, Medical University of South Carolina, 173 Ashley Ave., MSC509, Charleston, SC 29425, USA. Hauptthemen laut MEDLINE: Unfolded Protein Response, Lymphoma, T-Cell, Cutaneous, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Cutaneous T-cell lymphoma (CTCL) is a rare T-cell malignancy characterized by inflamed and painful rash-like skin lesions that may affect large portions of the body’s surface. Patients experience recurrent infections due to a compromised skin barrier and generalized immunodeficiency resulting from a dominant Th2 immune phenotype of CTCL cells. Given the role of the unfolded protein response (UPR) in normal and malignant T-cell development, we investigated the impact of UPR-inducing drugs on the viability, transcriptional networks, and Th2 phenotype of CTCL. We found that CTCL cells were >5-fold more sensitive to the proteasome inhibitor bortezomib (Btz) and exhibited a distinct signaling and transcriptional response compared to normal CD4+ cells. The CTCL response was dominated by the induction of the HSP70 family member HSPA6 (HSP70B’) and, to a lesser extent, HSPA5 (BiP/GRP78). To understand the significance of these two factors, we used a novel isoform selective small-molecule inhibitor of HSPA5/6 (JG-023). JG-023 induced pro-apoptotic UPR signaling and enhanced the cytotoxic effects of proteasome inhibitors and other UPR-inducing drugs in CTCL but not normal T cells. Interestingly, JG-023 also selectively suppressed the production of Th2 cytokines in CTCL and normal CD4+ T cells. Conditioned media (CM) from CTCL were immunosuppressive to normal T cells through an IL-10-dependent mechanism. This immunosuppression could be reversed by JG-023, other HSP70 inhibitors, Btz, and combinations of these UPR-targeted drugs. Our study points to the importance of the UPR in the pathology of CTCL and demonstrates the potential of proteasome and targeted HSPA5/6 inhibitors for therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Immunology, Medical University of South Carolina, 173 Ashley Ave., MSC509, Charleston, SC 29425, USA.
- Department of Pharmacology and Therapeutics, Center for Inflammation Science and Systems Medicine, University of Florida Scripps Institute for Biomedical Innovation and Technology, Jupiter, FL 33458, USA.
- Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.
- Zucker Institute for Innovation Commercialization, Charleston, SC 29425, USA.
ORCID-Profile: Nadia St Thomas, Lena Golick, Xiaoyi Zhu, Eli Chapman
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
St Thomas, N., Christopher, B. N., Reyes, L., Robinson, R. M., Golick, L., Zhu, X., Chapman, E., & Dolloff, N. G. (2025). Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma. Biomolecules. https://doi.org/10.3390/biom15010076
Vancouver
St Thomas N, Christopher BN, Reyes L, Robinson RM, Golick L, Zhu X, et al. Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma. Biomolecules. 2025. doi:10.3390/biom15010076
BibTeX
@article{StThomas2025,
author = {St Thomas, Nadia and Christopher, Benjamin N and Reyes, Leticia and Robinson, Reeder M and Golick, Lena and Zhu, Xiaoyi and Chapman, Eli and Dolloff, Nathan G},
title = {Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15010076}
}
EUVIMED